Antigen News and Research

RSS

Novel Base-Editing Approach Shows Promise for Inherited Motor Neuron Disorders

A team of researchers led by Professor Haruhisa Inoue (Center for iPS Cell Research and Application, Kyoto University) and Professor Yuishin Izumi (Tokushima University) demonstrated that adenine base editing can correct a disease-causing genetic mutation and alleviate neurodegeneration in hereditary motor and sensory neuropathy with proximal dominant involvement (HMSN-P), providing proof of concept for a precision gene therapy for inherited motor neuron diseases.

21 Sep 2026

Researchers Reveal How p53 Tumor-Suppressor Protein Hide From T Cells

One of the biggest challenges in cancer immunotherapy may not be that immune cells are too weak, but that some tumors give them too little to see.

18 Sep 2026

UCLA Breakthrough Generates Thousands of Allogeneic T-Cell Doses From Single Cord Blood Sample

T cell receptor, or TCR, therapy is a cancer treatment that genetically reprograms immune cells, called T cells, to hunt down cancer with precision.

9 Sep 2026

New Platform Promises Rapid Vaccine Monitoring and Biomarker Discovery for Emerging Pathogens

A research team comprising Associate Professor FUNAKOSHI Yohei, Associate Professor YAKUSHIJIN Kimikazu, Professor MINAMI Hironobu, and Associate Professor OHJI Goh of Kobe University, together with graduate student MASUDA Genki, then-graduate student IIZUMI Shunsuke, Associate Professor OHUE Masahito, and colleagues at the Institute of Science Tokyo, has developed a new analysis method, LM-QASAS.

9 Sep 2026

Research Maps Complex Molecular Rules Governing Specialized Tumor Immunity

For decades, natural killer (NK) cells have been classified into two main groups based on surface markers: one specialized for cytokine production and the other for direct killing.

7 Sep 2026

Essential SNX5 Protein Alerts Human Immune Cells to Tuberculosis Infections

Researchers at UT Southwestern Medical Center have identified a protein that helps the immune system respond to tuberculosis (TB), one of the world's leading infectious diseases.

31 Aug 2026

Novel T-Cell Engineering Strategy Prevents Deadly Osteosarcoma Lung Metastasis

Scientists at St. Jude Children's Research Hospital have discovered that removing the gene for Regnase-1 from engineered immune cells makes them more effective at treating relapsed osteosarcoma.

26 Aug 2026

AI Models Zero In on Antibody Binding Regions to Improve Drug Target Predictions

Focusing on complementarity-determining regions in antibody models leads to better binding affinity predictions, potentially accelerating treatment discovery.

20 Aug 2026

Mapping Functional Polyprotein Cleavage Sites Solves Post Infection Testing Dilemmas

Current coronavirus diagnostics mainly rely on nucleic acid amplification, antibody detection, or viral antigen detection.

17 Aug 2026

Novel Approach Provides a Flexible Foundation for Measuring Coronavirus Protease Activity

A research team has computationally designed a synthetic peptide that enables modular detection of the enzymatic activity of coronavirus 3C-like protease (3CLPro), an enzyme essential for viral replication and maturation.

13 Aug 2026

Modulating T Cell Exhaustion Offers Novel Therapeutic Pathways in Transplantation

A comprehensive new review examines the complex role of T cell exhaustion in organ transplantation, highlighting how this dysfunctional immune state can both promote graft tolerance and create vulnerabilities to infection and malignancy.

7 Aug 2026

Newly Identified Protein Prevents T Cells From Destroying Cancer Cells

Researchers at Mayo Clinic have identified a protein that cancer cells use to suppress the body's immune response, a finding that could support the development of new treatments to improve the effectiveness of cancer immunotherapies.

5 Aug 2026

Microneedle Patches Turn Skin Into a Window for Immune Bioanalysis

Researchers combined local restimulation of skin-resident memory T cells with hydrogel-coated microneedle patches to recruit and sample rare immune cells. In mouse models, the approach recovered more antigen-specific T cells than a blood sample or punch biopsy, while studies in humans supported short-term tolerability and proof-of-concept cell sampling.

28 Jul 2026

3D Mapping of Tonsil Genetic Structures Unlocks Antibody Optimization

About 2 meters worth of genetic material must fit into the nucleus of each and every one of most of our trillions of cells, coiling and winding to form what looks like a tangled mess.

28 Jul 2026

Deep-Learning Holography Detects Elusive Circulating Tumor Cells in Prostate Cancer

Researchers combined microfluidic enrichment, AI-assisted holography, and fluorescence profiling to identify circulating tumor cell candidates in 13 men with metastatic castration-resistant prostate cancer and 8 healthy donors. The platform found higher median candidate counts in patients, while nearly two-thirds of PSMA-positive candidates lacked EpCAM, suggesting EpCAM-dependent assays could miss some cells.

27 Jul 2026

Evaxion Presents New Preclinical Data for Cytomegalovirus Vaccine Program EVX-V1

Evaxion A/S (“Evaxion”), a clinical-stage TechBio company developing novel vaccines with its pioneering AI-Immunology™ platform, presents new data further supporting the multi-component concept of its cytomegalovirus (CMV) vaccine program EVX-V1.

14 Jul 2026

New ATTACH System Overcomes Key Bottleneck in Personalized Immunotherapy Development

A new platform developed by researchers at The University of Texas MD Anderson Cancer Center quickly finds and isolates rare, tumor-reactive immune cells that are especially good at recognizing and attacking cancer cells, even without knowing which tumor targets are recognized by the immune cells.

9 Jul 2026

Eradicating Lingering Cancer Cells Prevents Relapse in B Cell Leukemia

Researchers at The University of Texas MD Anderson Cancer Center were able to eradicate measurable residual disease (MRD) in B-cell acute lymphoblastic leukemia (ALL) patients, a critical step in improving long-term survival outcomes, by treating with the antibody-drug conjugate (ADC) inotuzumab ozogamicin.

9 Jul 2026

Antibody Drug Conjugate Treatment Destroys Hidden B Cell Leukemia

By using the antibody-drug conjugate (ADC) inotuzumab ozogamicin to treat B-cell acute lymphoblastic leukemia (ALL) patients, researchers at The University of Texas MD Anderson Cancer Center were able to eliminate measurable residual disease (MRD), a crucial step in enhancing long-term survival outcomes.

8 Jul 2026

Study: Genetically Engineered CAR T Cells Suppress the Immune System’s Response to Allergen

Genetically engineered CAR T cells expressing artificial receptor proteins are increasingly used in the clinic to boost the immune system's response against leukemias and other cancers.

7 Jul 2026